Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an
acquired immune-mediated inflammatory disorder of the peripheral
nervous system. In CIDP, the myelin sheath, the protective covering
of the nerves, is damaged. This may result in numbness or tingling,
muscle weakness, fatigue, and other symptoms. CIDP effects can
worsen over time, leading to significant activity limitations and a
decreased quality of life. CIDP can occur at any age and is more
common in men than in women. Approximately 30 percent of CIDP
patients will progress to wheelchair dependence if not treated. In
the U.S., it is estimated that the incidence of CIDP is up to two
patients per 100,000 people each year, with a prevalence of 40,000
people affected. Despite available treatment options, many CIDP
patients continue to struggle with daily disease and lifestyle
challenges. Fortunately for these patients, novel immunoglobulin
replacement therapies have recently become available that have shown
improved efficacy and safety as a maintenance therapy in CIDP. With
this new option comes a knowledge gap among physician medical
directors, neurologists and nurse case managers as the treatment
paradigm is growing.
First-line treatment for CIDP is currently intravenous
immunoglobulin (IVIG) and other treatments include corticosteroids
(e.g. prednisone), and plasmapheresis (plasma exchange) which may be
prescribed alone or in combination with an immunosuppressant drug.
However, recent controlled studies show how subcutaneous
immunoglobin (SCIG), which has only recently become available for
patients with CIDP, appears to be as effective for CIDP treatment as
IVIG in most patients, and with fewer systemic side effects.
Effective and timely treatment of CIDP can greatly improve the
quality of life and outcomes in CIDP patients.
Upon completion of this
activity, participants will be able to:
Review the pathophysiology and
symptomatology of chronic inflammatory demyelinating
polyneuropathy (CIDP) and its variants
Discuss the unmet needs and total
cost of care for CIDP, including direct costs associated with
drug therapy and associated infections from non-treatment, as
well as indirect costs
Analyze the safety and efficacy of
currently available and emerging immunoglobulin (Ig) replacement
therapies for the management of CIDP and apply them to patient
cases using evidence-based medicine
Compare and contrast the use of IVIG
and SCIG in the management of CIDP
Employ shared decision-making when
choosing treatment for patients with CIDP in the initial
management and maintenance settings
Assess managed care considerations
of Ig replacement therapies by exploring where these agents and
their varying administration fit into current CIDP management
||Chafic Karam, MD
Penn Neuroscience Center
Perelman Center for Advanced Medicine
serves on as a consultant for Alnylam, Akcea, CSL
Behring, Argenx, Biogen, and Genzyme. His presentation
has been peer reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue